Form 4: Zura Bio Director Steven J. Schoch Acquires Share Options
SEC Form 4 Filing
Director Steven J. Schoch of Zura Bio Ltd. reports acquisition of share options.
Summary
- Steven J. Schoch, a director of Zura Bio Ltd, filed a Form 4 with the SEC.
- The filing reports the acquisition of 51,000 share options on May 21, 2025.
- The exercise price of the options is $1.03.
- The options vest in twelve equal monthly installments over one year from the grant date, with potential for accelerated vesting before the next annual shareholder meeting.
- The options expire on May 21, 2035.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing reporting a routine transaction.
Positives
- The acquisition of share options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The acquisition of share options by a director may positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of earliest transaction (acquisition of share options). |
| 05/21/2025 | Share option grant date. |
| 05/22/2025 | Date of signature on the Form 4 filing. |
| 05/21/2035 | Expiration date of the share options. |
Keywords
Zura Bio, Director, Share Options, Form 4, SEC Filing, Beneficial Ownership, Schoch, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.